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ABSTRACT: The formation of reactive oxygen species
(ROS) is linked to the pathogenesis of neurodegenerative
diseases. Here we have investigated the effect of soluble
and aggregated amyloid-β (Aβ) and α-synuclein (αS),
associated with Alzheimer’s and Parkinson’s diseases,
respectively, on the Cu2+-catalyzed formation of ROS in
vitro in the presence of a biological reductant. We find that
the levels of ROS, and the rate by which ROS is generated,
are significantly reduced when Cu2+ is bound to Aβ or αS,
particularly when they are in their oligomeric or fibrillar
forms. This effect is attributed to a combination of radical
scavenging and redox silencing mechanisms. Our findings
suggest that the increase in ROS associated with the
accumulation of aggregated Aβ or αS does not result from
a particularly ROS-active form of these peptides, but rather
from either a local increase of Cu2+ and other ROS-active
metal ions in the aggregates or as a downstream
consequence of the formation of the pathological amyloid
structures.
A hallmark of the two major neurodegenerative disorders,Alzheimer’s disease (AD) and Parkinson’s disease (PD), is
the deposition within the brain of the amyloid β peptide (Aβ)
and α-synuclein (αS), respectively.1 Despite the difference in
the specific protein found to be the main component of the
amyloid deposits in AD and PD, the formation of the
pathological aggregates appears to occur via a common
misfolding and self-assembly process.1 The cytotoxic species
involved in both diseases appear to be the soluble oligomeric
intermediates that form during the process of amyloid
formation. Although the precise mechanism responsible for
the toxicity of such species is not fully established, increasing
evidence suggests that the neuronal cell loss in AD and PD is at
least in part linked to excessive free radical generation.2
Aβ and αS bind metal ions, including Cu2+, that promote
oligomerization and amyloid formation by both polypepti-
des3−5 and catalyze the formation of reactive oxygen species
(ROS) that cause oxidative damage. In the brains of both AD
and PD patients, increased oxidative damage, including protein,
DNA, and RNA oxidation and lipid peroxidation, is observed
relative to healthy controls.6−8 Impaired copper and iron
homeostasis has also been associated with AD and PD, with
elevated levels of both metals being found in the senile plaques
from AD patients and in the Lewy bodies and cerebrospinal
fluid of PD patients,9−11 which has stimulated interest in
understanding the interaction of Aβ and αS with metal ions and
its implications in AD and PD.
The coordination of Cu2+ to soluble Aβ and αS has been
characterized in atomic detail. In Aβ, Cu2+ is primarily
coordinated to Asp1, His6, His13, and His14 at physiological
pH.12,13 In αS, a high affinity binding site has been identified,
involving the first nine residues at the N-terminus.14,15 This
binding site is, however, inactivated when the N-terminus is
acetylated,16 but two low affinity binding sites in the vicinity of
residues His50 and Asp121 bind Cu2+ in the acetylated form of
αS found in vivo.16−18 It has been proposed that Cu2+
coordinated to Aβ and αS, in the presence of physiological
reductants such as ascorbate, catalyzes the reduction of
molecular oxygen to H2O2 and hydroxyl radicals (HO
•) via
Fenton chemistry (Figure 1). The coordination of Cu+ is
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Figure 1. Fenton reaction cycle for the production of ROS from
molecular oxygen and ascorbate (Asc); see ref 20
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different from that of Cu2+ for both Aβ and αS. In Aβ, Cu+ is
only coordinated to His13 and His14,13 and in αS, it is
primarily coordinated to the side chains of Met1, Asp2, and
Met5.19 Thus, the change in the oxidation state of Cu during
the Fenton reaction cycle will induce structural changes in the
protein−Cu complexes. The more ordered aggregated states of
Aβ and αS may shift the energy difference between the Cu+ and
the Cu2+ complexes relative to the flexible monomeric states
and potentially influence the kinetics of ROS formation.
Here we have explored how the Cu2+ interaction with
different aggregated states of Aβ and αS affect ROS production
in the presence of 100 μM ascorbate. We used a 2:1 protein/
Cu2+ molar ratio to avoid the presence of free Cu2+ in solution.
No detectable ROS production was observed in the samples
without the addition of Cu2+ and ascorbate (Figure S1). We
measured the production of both H2O2 and HO
• with
colorimetric and fluorescence assays and also followed the
consumption of ascorbate as a direct assay of ROS production.
Aβ40 and αS were studied, along with variants deficient in the
ability of bind Cu2+, namely, Aβ40[H6A/H13A/H14A], where
the Cu2+-coordinating histidine residues in Aβ were all
substituted by alanine, and αSΔ2−9, where residues 2−9 in
αS were deleted. Aggregated Aβ and αS fibrils were prepared
both in the absence and presence of Cu2+. In addition, αS
oligomeric species with structural features that are intermediate
between the intrinsically disordered monomeric protein and the
highly organized mature fibrils21 were included in the analysis.
These oligomeric forms of αS induce ROS production when
internalized in healthy neuronal cells.21,22 The mechanism of
αS-oligomer-induced ROS production has been linked to the
presence of free metal ions in the culture media.23
The rates and the levels of ROS production were highly
dependent on which form of Aβ or αS was present in the
solution. In the absence of protein, all ascorbate was consumed
within approximately 10 min (Figure 2A,B). The presence of
Aβ40[H6A/H13A/H14A], which does not bind Cu
2+, had no
effect on the ascorbate consumption rate (Figure S2A). Only
very small effects on ascorbate consumption were seen on
addition of monomeric and oligomeric αSΔ2−9 to the Cu2+/
ascorbate reaction mixture (Figure S2B). The rate of ascorbate
consumption, however, decreased 2- to 3-fold when Cu2+ was
bound to soluble wt-Aβ40 or wt-αS. The rate was reduced even
more (5-fold) when Cu2+ was bound to either oligomeric or
fibrillar states of Aβ40 and αS (Figures 2A,B and S3). The most
pronounced effects were monitored for Aβ40 and αS fibrils that
were formed in the presence of Cu2+, which produced ROS at a
rate decreased nearly 20-fold relative to that for the same
concentration of free metal ions in solution (Figures 2A,B and
S3). Even for αSΔ2−9, the fibrils formed in the presence of
Cu2+ reduced the rate of ascorbate consumption more than any
other αSΔ2−9 species (Figure S2).
The formation of H2O2 (Figure 2C,D) closely followed the
consumption of ascorbate and reached the same level for all
states of the proteins. In contrast, not only the rate but also the
final levels of HO• varied between the samples, with lower rates
being associated with lower final levels of the radical (Figure
2E,F). Fibrils of Aβ40 completely abolished the generation of
free HO• species that could react with 3-CCA. In addition, the
fibrils of αS that were formed in the presence of Cu2+ resulted
in very low levels of free HO•. Moreover, in the presence of
Cu2+, the oligomers of αS lowered the level of HO• to the same
extent as that of fibrils of αS formed in the absence of Cu2+
(compare Figure 2F blue and gray curves). Together, the data
suggest that Cu2+ is less accessible to the solvent when bound
to the aggregated forms of Aβ40 and αS than when bound to
the monomeric state, and much less than when free in solution;
hence, it is less able to react with ascorbate, resulting in slower
ROS formation. Although all ascorbate was consumed and the
same levels of H2O2 were produced at the end of the reaction
under all conditions, significant differences in the amount of
free HO• were observed, which correlates with the variations in
the initial rate of ROS production by the different protein
species. This observation suggests that the proteins act as
efficient scavengers of HO• produced by Cu2+−protein
complexes.
To confirm that the proteins do indeed act as radical
scavengers and to characterize the covalent modifications of
Aβ40 and αS induced by the oxidation, we monitored the time-
dependent changes in molecular mass using MALDI-TOF MS
(Figures 3 and S4). In the presence of Cu2+ and ascorbate, we
observed a low level of oxidation and cleavage of αS. The
oxidative patterns for monomeric, oligomeric, and fibrillar states
of αS are similar to each other, although the monomer
demonstrates a slightly higher level of oxidation (Figure 3D).
More oxidation and oxidation-driven cleavage of the polypep-
tide chain are evident for Aβ40. Here, an intense peak in the
mass spectrum corresponding to cleavage of the peptide
backbone between the Cu2+ coordination residues His13 and
Figure 2. Generation of ROS in the presence of Aβ40 and αS. (A and
B) Consumption of ascorbate, measured by the decrease in absorbance
at 265 nm, for (A) Aβ40 and (B) αS. (C and D) Generation of H2O2,
measured by the increase in resorufin fluorescence at 590 nm, for (C)
Aβ40 and (D) αS. (E and F) The formation of HO
• was measured by
the increase in fluorescence at 450 nm upon oxidation of 3-CCA for
(E) Aβ40 and (F) αS. Seven different conditions were employed (red,
monomeric protein; black, fibrils formed in the absence of Cu2+; gray,
fibrils formed in the presence of Cu2+; blue, oligomers (αS only);
purple, Cu2+ alone; orange, ascorbate alone; and green, Cu2+ and
ascorbate alone). In all assays, the concentrations of protein, Cu2+, and
ascorbate were 10, 5, and 100 μM, respectively.
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His14 appears within the first 30 min of the redox reaction
(Figure 3B), in agreement with previous observations.24,25
More oxidation is observed for monomeric Aβ40 than for αS,
consistent with the results from the 3-CCA assay, which show
that the level of free HO• is lower in the Aβ40 samples than in
the corresponding αS samples and that Aβ thus more readily
reacts with HO• (compare Figure 2E,F). Our results, therefore,
indicate that Aβ40 is more efficient than αS as an HO
•
scavenger.
The slower ROS formation and lower free HO• levels in the
presence of fibrils cannot be fully explained by the fibrils acting
as more efficient ROS scavengers than the soluble species. If
this were the case, then we would not expect the ascorbate
consumption to be slowed down. Furthermore, we observe
more oxidized species in the monomeric samples than in the
fibrillar samples. The effect of the Aβ40 and αS fibrils, and αS
oligomers, is rather to sequester Cu2+ from the solution and
decrease the rate of Cu redox cycling.
Aβ40 and αS have previously both been suggested to act as
pro-oxidants,14,20,26 and Aβ40 has also been suggested to act as
an antioxidant.27,28 The main argument for αS and Aβ40 acting
as pro-oxidants is that higher levels of free radicals are produced
when Cu2+ is bound to these proteins than when Cu2+ is bound
to other peptides or proteins. In contrast, the main argument
for Aβ40 acting as an antioxidant is that less free radicals are
produced by Cu2+ bound to Aβ40 relative to those from free
Cu2+. Here we have shown that both Aβ40 and αS, when bound
to Cu2+, reduce the ROS levels as compared to free Cu2+. This
reduction is likely to be related to the binding of Aβ40 and αS to
Cu2+ because the ROS levels of Cu2+ in the presence of
monomeric Aβ40[H6A/H13A/H14A] and αSΔ2−9 are very
similar to those in the presence of free Cu2+ (Figure S2). We
have also shown that the oligomeric and fibrillar samples of
Aβ40 and αS are much more efficient than soluble species at
reducing the HO• levels in solution.
Our data show that Aβ40 and αS both serve as HO
•
scavengers, because they reduce the amount of free HO• in
the solution, and that the binding of Cu2+ to the proteins
decreases ROS production. These effects become more
prominent when Cu2+ is bound to the β-sheet-rich con-
formations of the aggregates in both Aβ40 and αS. It is likely
that the compact structure of the aggregates prevents
accessibility of oxygen and ascorbate to Cu2+ and, therefore,
suppresses electron transfer from the metal ions to oxygen
molecules. This notion is supported by EPR and ESEEM data
that suggest that the preferred Cu2+ coordination mode in both
soluble and aggregated Aβ40 is unfavorable for Cu
+/Cu2+ redox
cycling.29 As a consequence, ROS production mediated by Cu2+
will be decreased when Cu2+ is coordinated to Aβ40 and in
particular when coordinated to Aβ40 fibrils. Furthermore, the
decrease in redox activity in the aggregated state may reflect the
fact that redox cycling of coordinated Cu+ and Cu2+ requires
formation of a transient intermediate coordination state where
the coordination sphere differs from the resting states of Aβ−
Cu+/2+.12 If the free energy barrier for formation of this
transient state is increased in the aggregated species, e.g., as a
result of a decrease in flexibility of the coordination sphere,
then the redox activity of Cu2+ coordinated to aggregated Aβ40
or αS will decrease.30 Formation of the transient intermediate
state may be further inhibited by the increase in the number of
Cu2+ coordination modes in the aggregates compared to the
soluble proteins.31
Using two different amyloidogenic proteins, we have
demonstrated that Cu2+-catalyzed ROS formation is signifi-
cantly reduced when the metal ion is bound to aggregated
species, which also act as HO• scavengers. Although we and
others have previously shown that certain amyloid aggregates
such as those used in this study are able to induce more
aberrant ROS production than are monomeric species when
internalized in cells,22,23,32 the in vitro data presented here
reveal that this is likely not to be a consequence of direct ROS
formation catalyzed by the aggregates but rather a downstream
consequence of a primary effect of these aggregates on the cells.
Nevertheless, some ROS is produced from Cu2+ bound to
aggregates, and as a result of the high concentrations of amyloid
species in plaques and Lewy bodies, ROS may increase locally
in the regions of amyloid accumulation, although relative to
Cu2+ that is freely diffusing or even bound to physiological
forms of Aβ40 or αS, the aggregates will strongly attenuate the
ROS formation.
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L.; Dyba, M. J. Inorg. Biochem. 2004, 98, 940.
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